within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J04A_DrugsForTreatmentOfTuberculosis.J04AC01_Isoniazid;

model Isoniazid
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.9,
    Cl = 3.6111111111111115e-06,
    adminDuration = 600,
    adminMass = 300 / 1000000,
    adminCount = 1,
    Vd = 0.0006,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0125,
    Tlag = 900);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Isoniazid</td></tr><tr><td>ATC code:</td><td>J04AC01</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>300</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.6</td><td>L</td></tr>
    <tr><td>clearance:</td><td>13</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Isoniazid is a bactericidal antibiotic used primarily as a first-line agent for the prevention and treatment of tuberculosis. It is generally approved and used today, often in combination with other antitubercular medications.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers, both sexes, after single oral dose.</p><h4>References</h4><ol><li><p>Chen, B, et al., &amp; Cai, WM (2022). Population Pharmacokinetics and Pharmacodynamics of Isoniazid and its Metabolite Acetylisoniazid in Chinese Population. <i>Frontiers in pharmacology</i> 13 932686–None. DOI:<a href=\"https://doi.org/10.3389/fphar.2022.932686\">10.3389/fphar.2022.932686</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35928262/\">https://pubmed.ncbi.nlm.nih.gov/35928262</a></p></li><li><p>Sullins, AK, &amp; Abdel-Rahman, SM (2013). Pharmacokinetics of antibacterial agents in the CSF of children and adolescents. <i>Paediatric drugs</i> 15(2) 93–117. DOI:<a href=\"https://doi.org/10.1007/s40272-013-0017-5\">10.1007/s40272-013-0017-5</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/23529866/\">https://pubmed.ncbi.nlm.nih.gov/23529866</a></p></li><li><p>Wilkins, JJ, et al., &amp; Simonsson, US (2011). Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients. <i>British journal of clinical pharmacology</i> 72(1) 51–62. DOI:<a href=\"https://doi.org/10.1111/j.1365-2125.2011.03940.x\">10.1111/j.1365-2125.2011.03940.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/21320152/\">https://pubmed.ncbi.nlm.nih.gov/21320152</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.J.J04AC01 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Isoniazid;
